Compare Amgen, Inc. (AMGN) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs MINISO Group Holding Ltd — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while MINISO Group Holding Ltd trades at $11.47 (market cap $3.51B). The key difference: Amgen, Inc. is far larger — about 55.9× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (5.65%). Which is the better fit depends on your goals.
| AMGN | MNSO | |
|---|---|---|
Market Cap | $196.12B | $3.51B |
Sector | Health | Technology |
52-Week High | $388.16 | $26.63 |
52-Week Low | $271.18 | $11.30 |
Enterprise Value | $241.41B | $4.17B |
Dividend Yield | 2.77% | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
MNSO trades at $11.79, up 2.79% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings, beating expectations with EPS of $0.591, and announced a HK$2 billion share repurchase program on June 29, 2026. Revenue grew to $21.44 billion in 2025, with a net income margin of 8.98% and a P/E ratio of 12, indicating potential undervaluation.
The outlook is mixed: analyst consensus is 75% buy with growth potential from overseas expansion, but risks include margin compression and recent earnings misses. The stock's current price near the lower end of its 52-week range suggests caution amid bearish technical trends, though fundamentals support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
